AbbVie (ABBV)

The choice between the two might come down to each investor's goals and risk tolerance.

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.

The company sure knows what to do before and after a blockbuster drug tumbles off the patent cliff.

In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx Biosciences (NASDAQ: VTYX) for approximately $1.2 billion. The all-cash deal, announced in early January 2026, values Ventyx at $14.00

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market value in a single trading session. This volatility was on full display in late January 2026 as Revolution Medicines (Nasdaq: RVMD) experienced a dramatic 20% stock [...]

These stocks offer highly attractive dividends and staying power.

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]

These stocks offer yields of more than double the S&P 500 average.

These stocks offer impressive long-term upside with downside protection.

As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On the eve of its official fourth-quarter and full-year 2025 earnings release scheduled for January 21, 2026, the company has already signaled

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

All three of these healthcare giants are leaders in their niches.

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]

Income investors can rely on these stocks.

These stocks sport dividend yields ranging from 2.9% to 5.5%.

This healthcare giant is a top pick for growth and dividend investors.

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

These stocks could have plenty of upside for investors who invest in these businesses today.

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with

Retail sentiment remained mixed on Stocktwits, with a neutral view on SPY but growing bullishness around QQQ.